Comments on: Beware the unintended consequences http://www.medrants.com/archives/2104 Internal medicine, American health care, and especially medical education Sat, 11 Feb 2012 15:15:48 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: pj http://www.medrants.com/archives/2104/comment-page-1#comment-4726 pj Mon, 04 Oct 2004 04:12:59 +0000 http://medrants.com/archives/2004/09/29/beware-the-unintended-consequences/#comment-4726 i rarely attend local CME's.. almost all comes from annual review courses and specialty updates. unfortunately, the average course is about 1,300 dollars. these courses have no pharma sponsorship and are generally well attended..attendance would even be better if the costs were lower. i rarely attend local CME’s..
almost all comes from annual review courses and specialty updates. unfortunately, the average course is about 1,300 dollars. these courses have no pharma sponsorship and are generally well attended..attendance would even be better if the costs were lower.

]]> By: arf http://www.medrants.com/archives/2104/comment-page-1#comment-4698 arf Wed, 29 Sep 2004 23:05:15 +0000 http://medrants.com/archives/2004/09/29/beware-the-unintended-consequences/#comment-4698 I remember looking at a "symposium" supplement to one of the better-respected throwaways, back about 1998. It was about chronic pain management. All the evils of opiate prescribing, the growing oxy-contin concerns, the legal traps you can fall into, etc. And, of course, the benefits of using some of the "newer" NSAID's on the market. How safe they are compared to the older NSAID's and the opiates. It was clear the supplement was sponsored by the makers of DURACT (bromfenac). The cool part was, by the time I got 'round to looking at the supplement, Duract had already been pulled off the market. I remember looking at a “symposium” supplement to one of the better-respected throwaways, back about 1998.

It was about chronic pain management. All the evils of opiate prescribing, the growing oxy-contin concerns, the legal traps you can fall into, etc. And, of course, the benefits of using some of the “newer” NSAID’s on the market. How safe they are compared to the older NSAID’s and the opiates.

It was clear the supplement was sponsored by the makers of DURACT (bromfenac).

The cool part was, by the time I got ’round to looking at the supplement, Duract had already been pulled off the market.

]]> By: SteveSC http://www.medrants.com/archives/2104/comment-page-1#comment-4697 SteveSC Wed, 29 Sep 2004 19:21:27 +0000 http://medrants.com/archives/2004/09/29/beware-the-unintended-consequences/#comment-4697 The attempts to control pharma marketing are similar to attempts to control political spending. When you squeeze the balloon in one spot it just bulges someplace else. Next step--the medical equivalent of 527 organizations? The attempts to control pharma marketing are similar to attempts to control political spending. When you squeeze the balloon in one spot it just bulges someplace else. Next step–the medical equivalent of 527 organizations?

]]> By: Robert W. Donnell http://www.medrants.com/archives/2104/comment-page-1#comment-4696 Robert W. Donnell Wed, 29 Sep 2004 16:03:44 +0000 http://medrants.com/archives/2004/09/29/beware-the-unintended-consequences/#comment-4696 We’re pushing this issue to the extreme at the risk of throwing the baby out with the bathwater. Sooner or later the drug companies will say uncle and divert their marketing resources to consumer advertising. It’s already getting harder to obtain industry support for CME, which I suspect is one of the reasons the American College of Cardiology is considering discontinuing all extramural CME programs. What will be next? Expert speakers at Grand Rounds? Meet the Professor sessions? Medscape? In fact, why not save a lot of money at these meetings and just bring in a medical librarian to lead the audience through Pub Med searches of various topics? We’re pushing this issue to the extreme at the risk of throwing the baby out with the bathwater. Sooner or later the drug companies will say uncle and divert their marketing resources to consumer advertising. It’s already getting harder to obtain industry support for CME, which I suspect is one of the reasons the American College of Cardiology is considering discontinuing all extramural CME programs. What will be next? Expert speakers at Grand Rounds? Meet the Professor sessions? Medscape? In fact, why not save a lot of money at these meetings and just bring in a medical librarian to lead the audience through Pub Med searches of various topics?

]]>